Premier Submits Comments on DEA’s Proposed Quotas for Controlled Substances

Premier submitted comments cautioning the DEA to carefully consider how a reduction in manufacturing quotas for certain opioids could exacerbate recent drug shortages for injectable opioids and have a negative effect on patients with a legitimate and serious need for these medications. Earlier this month, the DEA proposed to lower the annual production quotas of several critical medications used in acute settings such as fentanyl. Echoing past comments to the DEA, Premier advocated for a complete overhaul of the quota allocation process, abandoning quotas based on weight in favor of establishing quotas based on dosage form and differentiating between injectables and solid oral dosage forms. Premier also urged the DEA to work with stakeholders to develop sustainable solutions that balance preventing diversion and abuse of opioids with ensuring adequate supply for clinically appropriate care.